SS-31 and Mitochondrial Research: Mechanisms, Trials, and Limits

SS-31 research spans laboratory experiments and studies of elamipretide in specific patient populations. This selected-study guide separates mechanisms, a clinical trial's negative primary results, and the evidence described in FDA's 2025 approval materials. It is not a complete clinical or regulatory review.

At a glance:

• A laboratory mechanism does not guarantee a clinical benefit.

• A randomized trial and an open-label extension have different limitations.

• Approval of a particular medicine does not establish equivalence of a research vial.

Publisher disclosure: Bio Research LLC operates Bio Peptides Labs. This commercially interested, AI-assisted summary is not an independent scientific review. Source-access limits appear below.

1. What do SS-31 and elamipretide refer to?

Research literature identifies elamipretide as SS-31, a synthetic four-amino-acid peptide. A 2020 mechanistic paper uses both names while investigating interactions within mitochondria. This establishes the terminology used in that paper, not the identity or equivalence of every product carrying either name. Chavez and colleagues, 2020

For material comparison, start with the exact chemical identity, formulation, and supporting lot documents. Keep those checks separate from whether a study's biological result is relevant to a research question.

2. What did cardiolipin experiments show?

Cardiolipin is a membrane lipid studied in mitochondrial function. Birk and colleagues investigated SS-31 using model membranes and mitochondrial preparations. They reported interactions with cardiolipin-containing membranes and effects on electron transfer, oxygen consumption, and production of ATP, a molecule cells use to transfer energy. These results describe the experimental conditions studied. 2014 study record, abstract at the authors' institution

These were controlled biochemical and mitochondrial experiments, not measurements of how energetic a person felt. The distinction matters because an assay of ATP production and a patient-reported symptom are not interchangeable endpoints.

A later study used biotin-labeled SS-31, a version with an added tag to help recover the material for analysis. Researchers chemically linked nearby molecules and analyzed them by mass spectrometry in isolated mitochondria. They identified interactions with proteins involved in energy production and other metabolic processes. This modified probe's interaction map is not a clinical efficacy result. Chavez and colleagues, 2020

3. Why include a clinical trial that missed its endpoints?

MMPOWER-3 was a randomized, double-blind, placebo-controlled trial involving 218 participants with primary mitochondrial myopathy, a group of genetic mitochondrial disorders affecting muscle function. At 24 weeks, elamipretide did not meet its primary endpoints for six-minute walking distance and total fatigue. Karaa and colleagues, 2023 — original paper, PDF

Most adverse events were mild or moderate. However, adverse events led to treatment discontinuation in 8 of 109 elamipretide participants versus 2 of 109 placebo participants. Serious events occurred in both groups and were not deemed treatment-related. Stealth BioTherapeutics funded the trial. These qualifications matter; neither risk-free use nor safety of another formulation follows from the report. Safety results, Table 4, and funding disclosure — PDF

This result belongs beside the mechanistic studies, not hidden behind them. A plausible mechanism does not guarantee that a tested intervention will improve the outcomes selected in a clinical trial. Conversely, a result in one defined population should not be restated as a universal result across every disease or research model.

4. What about the approved medicine?

On September 19, 2025, FDA announced accelerated approval of Forzinity (elamipretide) for Barth syndrome in patients weighing at least 30 kilograms. FDA's trial snapshot specifies the indication as improving muscle strength in that population. This is a specific medicine and indication, not blanket approval for products labeled SS-31. FDA trial snapshot

The Barth syndrome study, SPIBA-201, enrolled 12 patients. FDA reports that its randomized phase did not demonstrate superiority on the primary walking-distance and fatigue endpoints. The strength increases were observed in the open-label extension, not the randomized phase. In an open-label extension, participants and researchers know the treatment being given; this limits interpretation compared with a blinded placebo-controlled comparison. FDA trial design and results

At approval, FDA required a confirmatory trial to establish patient benefit from the observed knee-muscle strength changes. Its announcement also reports injection-site reactions and serious reactions. This review does not establish whether the confirmatory requirement has subsequently been fulfilled. SPIBA-201 and MMPOWER-3 concern different patient populations and should not be combined as if they were one trial. FDA's September 2025 announcement

A research catalog listing is not proof that its contents are Forzinity. This article makes no equivalence claim, offers no treatment recommendation, and does not extend an approval to our inventory.

5. A practical way to read the next paper

Before carrying a conclusion into another context, write down:

• The material: exact molecule, formulation, or modified probe.

• The system: model membrane, isolated mitochondria, animal, or defined patient group.

• The endpoint: binding, respiration, function, symptoms, or another stated measure.

• The result: what changed, what did not, and what remains uncertain.

Then ask whether the proposed conclusion matches all four. This simple check helps prevent a mechanistic finding from becoming an unsupported product promise.

For separate material-documentation questions, use our COA, HPLC, and mass spectrometry guide and research peptide documentation checklist. Visit the research resource library for related guides.

Review method and source access

Sources checked September 27, 2026 include original-study abstracts, selected full-text sections, and FDA publications. Underlying datasets were not independently reanalyzed. This educational guide reports no new experiments and does not claim to cover every study or later regulatory development.

Bio Peptides Labs catalog materials are offered for lawful laboratory research only, not for human or veterinary use. No current inventory lot was tested or authenticated for this review.